Publication | Open Access

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Non-small-cell Lung CancerMedicineMetronomic TherapyClinical TrialsPathologyBronchial NeoplasmAtezolizumab Versus DocetaxelPharmacotherapyCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyPhase 3Health Sciences